Market Closed -
Toronto S.E.
16:32:40 21/06/2024 BST
|
5-day change
|
1st Jan Change
|
1.02
CAD
|
-6.42%
|
|
-4.67%
|
-27.14%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
95.56
|
47.54
|
12.44
|
9.431
|
10.35
|
14.61
|
Enterprise Value (EV)
1 |
23.67
|
35.66
|
11.17
|
6.906
|
6.346
|
8.786
|
P/E ratio
|
25.6
x
|
-3.33
x
|
-1.86
x
|
-13
x
|
7.71
x
|
-15.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.28
x
|
2.36
x
|
1.07
x
|
0.43
x
|
0.45
x
|
0.67
x
|
EV / Revenue
|
0.81
x
|
1.77
x
|
0.96
x
|
0.32
x
|
0.28
x
|
0.4
x
|
EV / EBITDA
|
-25.5
x
|
-5.49
x
|
-2.18
x
|
19.1
x
|
2.21
x
|
9.42
x
|
EV / FCF
|
0.37
x
|
-1.56
x
|
2.66
x
|
6.01
x
|
4.87
x
|
3.73
x
|
FCF Yield
|
270%
|
-64%
|
37.6%
|
16.6%
|
20.5%
|
26.8%
|
Price to Book
|
1.14
x
|
1.76
x
|
0.64
x
|
0.51
x
|
0.49
x
|
0.73
x
|
Nbr of stocks (in thousands)
|
15,538
|
10,804
|
10,451
|
10,251
|
10,251
|
10,436
|
Reference price
2 |
6.150
|
4.400
|
1.190
|
0.9200
|
1.010
|
1.400
|
Announcement Date
|
29/04/19
|
16/04/20
|
20/04/21
|
27/04/22
|
06/04/23
|
08/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
29.11
|
20.17
|
11.61
|
21.74
|
23.06
|
21.69
|
EBITDA
1 |
-0.927
|
-6.501
|
-5.132
|
0.361
|
2.873
|
0.933
|
EBIT
1 |
-1.226
|
-8.147
|
-7.686
|
-2.495
|
1.193
|
-0.854
|
Operating Margin
|
-4.21%
|
-40.39%
|
-66.2%
|
-11.47%
|
5.17%
|
-3.94%
|
Earnings before Tax (EBT)
1 |
4.823
|
-19.64
|
-6.845
|
-0.759
|
1.385
|
-0.897
|
Net income
1 |
3.926
|
-19.79
|
-6.845
|
-0.727
|
1.365
|
-0.922
|
Net margin
|
13.49%
|
-98.08%
|
-58.96%
|
-3.34%
|
5.92%
|
-4.25%
|
EPS
2 |
0.2400
|
-1.320
|
-0.6406
|
-0.0709
|
0.1310
|
-0.0900
|
Free Cash Flow
1 |
63.92
|
-22.83
|
4.2
|
1.15
|
1.303
|
2.353
|
FCF margin
|
219.58%
|
-113.19%
|
36.18%
|
5.29%
|
5.65%
|
10.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
318.49%
|
45.37%
|
252.18%
|
FCF Conversion (Net income)
|
1,628.22%
|
-
|
-
|
-
|
95.49%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/19
|
16/04/20
|
20/04/21
|
27/04/22
|
06/04/23
|
08/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
71.9
|
11.9
|
1.27
|
2.53
|
4.01
|
5.83
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
63.9
|
-22.8
|
4.2
|
1.15
|
1.3
|
2.35
|
ROE (net income / shareholders' equity)
|
4.78%
|
-35.8%
|
-29.7%
|
-3.87%
|
6.93%
|
-4.51%
|
ROA (Net income/ Total Assets)
|
-0.66%
|
-6.97%
|
-12.6%
|
-4.99%
|
2.56%
|
-1.84%
|
Assets
1 |
-596
|
283.8
|
54.39
|
14.56
|
53.37
|
50.06
|
Book Value Per Share
2 |
5.380
|
2.490
|
1.870
|
1.800
|
2.050
|
1.910
|
Cash Flow per Share
2 |
1.550
|
1.200
|
0.2600
|
0.3600
|
0.4700
|
0.6100
|
Capex
1 |
0.2
|
0.19
|
0
|
0.38
|
0.01
|
-
|
Capex / Sales
|
0.68%
|
0.92%
|
0.02%
|
1.73%
|
0.06%
|
-
|
Announcement Date
|
29/04/19
|
16/04/20
|
20/04/21
|
27/04/22
|
06/04/23
|
08/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -27.14% | 7.8M | | +16.45% | 123B | | +21.96% | 115B | | +23.73% | 25.85B | | -20.05% | 20.9B | | -16.28% | 16.77B | | -16.52% | 16.52B | | -44.35% | 15.56B | | +63.91% | 15.49B | | +2.52% | 13.45B |
Bio Therapeutic Drugs
|